Sarcoma
Welcome,         Profile    Billing    Logout  
 506 Companies   302 Products   302 Products   167 Mechanisms of Action   1360 Trials   122555 News 


«12...1718192021222324252627...15261527»
  • ||||||||||  Journal:  FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2. (Pubmed Central) -  May 15, 2024   
    Mechanistically, FBXO43 interacts with phosphorylated SKP2 induced by AKT1, leading to reduced SKP2 auto-ubiquitylation and subsequent proteasome degradation. Taken together, our study demonstrates that FBXO43 promotes cell cycle progression by stabilizing SKP2, and FBXO43 could serve as a potential anti-cancer target.
  • ||||||||||  Journal:  A rare case of epithelioid angiosarcoma. (Pubmed Central) -  May 15, 2024   
    Being a highly-aggressive tumor, an early diagnosis is challenging but essential to a successful treatment, warranting the need for suspicion of this neoplasm. An early core biopsy or surgical sample may expedite the diagnosis.
  • ||||||||||  Biomarker, Journal, Gene Signature:  Inflammasome-related gene signatures as prognostic biomarkers in osteosarcoma. (Pubmed Central) -  May 15, 2024   
    This research offers new insights into inflammasomes' role in osteosarcoma, introducing novel biomarkers for risk assessment and potential therapeutic targets. Our findings suggest a pathway towards personalised treatment strategies, potentially improving patient outcomes in osteosarcoma.
  • ||||||||||  Biomarker, Journal:  Cyclin D1 expression in penile cancer. (Pubmed Central) -  May 15, 2024   
    Patients with cyclin D1 expression exhibited lower disease-free survival compared to the cyclin D1-negative group, although the difference was not statistically significant. The results suggest that cyclin D1 may be a potential biomarker for PC, especially for poorer prognosis.
  • ||||||||||  methotrexate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Osteosarcoma cell death induced by innovative scaffolds doped with chemotherapeutics. (Pubmed Central) -  May 15, 2024   
    SrCPC demonstrates a good cytocompatibility and it induced upregulation of osteogenic genes involved in the skeletal development pathway, together with OCN protein expression and mineral matrix deposition. The proposed approach, based on the local, sustained release of anticancer drugs from nanostructured biomimetic drug-loaded cements is promising for future therapies aiming to combine bone regeneration and anticancer local therapy.
  • ||||||||||  Journal:  Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma. (Pubmed Central) -  May 15, 2024   
    While we do not dispute the recognition of PEComas as a distinct entity, we advocate the hypothesis that modified smooth muscle cells represent the origin of a subset of PEComas, and our case series provides evidence to suggest this theory. Compared to traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.
  • ||||||||||  camsirubicin (MNPR-201) / Monopar Therap
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  Camsirubicin + Pegfilgrastim to Determine MTD in ASTS (clinicaltrials.gov) -  May 15, 2024   
    P1,  N=14, Terminated, 
    We conclude that these aberrations in AXL are distinct features of MFS and may aid diagnosis, as well as the selection of available targeted therapies. N=21 --> 14 | Trial completion date: Jun 2025 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Oct 2023; lack of timely enrollment
  • ||||||||||  BTX-A51 / Edgewood Oncology
    New P1 trial, Metastases:  BTX-A51 in Patients With Liposarcoma (clinicaltrials.gov) -  May 15, 2024   
    P1,  N=12, Not yet recruiting, 
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, BioNTech
    CLINICAL COURSE OF COVID-19 IN PATIENTS WITH SPLENECTOMY () -  May 15, 2024 - Abstract #EHA2024EHA_4056;    
    Serologic response after COVID-19 infectionand/or vaccination was preserved in splenectomized patients. Vaccination has to be considered to overcomeincreased susceptibility or worse symptoms of COVID-19 infection in splenectomized individuals.
  • ||||||||||  SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN ELEVEN PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA () -  May 15, 2024 - Abstract #EHA2024EHA_1479;    
    Our center prospectively performed autologous HSCT in nine patients with AIDS-NHL, andthe results showed that the time of granulocyte and platelet engraftment was consistent with that of ordinaryNHL patients, with no transplant-related death and was well tolerated. Failure to achieve complete remissionbefore transplantation may be one of the adverse factors for the early death of patients.
  • ||||||||||  Retrospective data, Journal:  Imaging characteristics and diagnosis of primary middle mediastinal tumors (Pubmed Central) -  May 14, 2024   
    Mediastinal tumors have low incidence rate and rich histological types, and their imaging manifestations are diverse. Preoperative differential diagnosis can be made according to their specific imaging characteristics.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  FBXO22 is a potential therapeutic target for recurrent chondrosarcoma. (Pubmed Central) -  May 14, 2024   
    In addition, suppressing FBXO22 raised the expression of PD-L1 in Re-CHS. All these findings provide new evidence for using FBXO22 and PD-L1 as combined targets to prevent and treat Re-CHS, which may prove to be a novel strategy for immunotherapy of CHS, especially Re-CHS.
  • ||||||||||  Journal:  ATRX and Its Prognostic Significance in Soft Tissue Sarcoma. (Pubmed Central) -  May 14, 2024   
    This is consistent with studies in osteosarcoma, which indicate possible mechanisms through which loss of ATRX leads to more aggressive phenotypes. Future prospective clinical studies are required to validate the prognostic significance of these findings.
  • ||||||||||  Journal:  Transformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma. (Pubmed Central) -  May 14, 2024   
    We present a case report of a 51-year-old patient who was initially diagnosed with glioblastoma multiforme, which transformed into secondary gliosarcoma with an osteosarcoma component 16 months after the initial diagnosis. We believe that increasing reporting of secondary gliosarcoma (sGS) will be helpful in understanding, diagnosing and providing more effective treatment for this cancer.
  • ||||||||||  Journal:  Spontaneous expulsion of a (Pubmed Central) -  May 14, 2024   
    We believe that increasing reporting of secondary gliosarcoma (sGS) will be helpful in understanding, diagnosing and providing more effective treatment for this cancer. No abstract available
  • ||||||||||  Review, Journal:  Myositis ossificans mimicking bone surface osteosarcoma: case report with literature review. (Pubmed Central) -  May 14, 2024   
    Furthermore, immunohistochemistry fluorescence in situ hybridization and molecular testing can aid in the distinction of myositis ossificans from mimics. Because of their resemblance to other bone tumors, these cases of myositis ossificans highlight the importance of a multidisciplinary approach integrating clinical, radiologic, and pathologic analysis and involving serial imaging, sampling, and judicious use of ancillary immunohistochemical and molecular testing.